P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA

Lignende værker

• Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
  af: Jennifer M. Knight, et al.
  Udgivet: (2022-05-01)
• PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
  af: Joanna Zurko, et al.
  Udgivet: (2021-04-01)
• P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
  af: Nirav N Shah, et al.
  Udgivet: (2023-08-01)
• Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
  af: Nirav N. Shah, et al.
  Udgivet: (2019-03-01)
• The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation
  af: Mallory R. Taylor, et al.
  Udgivet: (2022-08-01)